Taken together that similar outcomes on β-catenin activity, EMT suppression, or breast cancer progression are achieved by inhibiting LRP6 or Rad6B [22], illustrate the cooperation between the canonical Wnt signaling pathway and Rad6B in β-catenin activation. This evidence concerns the gene LRP6 and breast carcinoma.